P-190 Personalized Immunotherapy with Cell-Encapsulation Technology for 2nd line R/M HNSCC: Safety and Early Efficacy Data from all HNSCC patients treated with MVX-ONCO-1 in two clinical trials. (July 2021) - Fernandez, Eugenio; Vernet, Remi; Charrier, Emily; Joerger, Markus; de Belkouch, Marie-Clau; Urwyler, Muriel; von Rohr, Olivier; Rubin, Olivier; Villard, Jean; Ancrenaz, Virginie; Grandjean, Nicole; Lavallière, Emmanuel; et al.